Cryptic splicing of stathmin-2 and UNC13A mRNAs is a pathological hallmark of TDP-43-associated Alzheimer's disease.

"Declarations Conflict of interestThe authors report no competing interests to declare. Conflict of interest The authors report no competing interests to declare."

"Funding ARAAQ is the recipient of a Postdoctoral Fellowship from the Alzheimer’s Disease Research Program of the BrightFocus Foundation (BrightFocus Grant Number A2022002F). ISN was the recipient of a fellowship from the Friedrich-Naumann Foundation. SA and MN were supported by the Cullen Education and Research Foundation Young Investigator Award. MN is supported by the Holloway Postdoctoral Fellowship from the Association for Frontotemporal Degeneration. MWB and MSB were both funded by Ruth Kirschstein Institutional National Research Service Awards (T32 GM008666 MWB and T32 AG 66596-2 MSB). MWB received support from the ALS association and ZM and JLE were awarded Muscular Dystrophy Association development grants. The Mayo RNA-seq study was led by Dr. Nilüfer Ertekin-Taner, Mayo Clinic, Jacksonville, FL as part of the multi-PI U01 AG046139 (MPIs Golde, Ertekin-Taner, Younkin, Price) using samples from the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, CurePSP Foundation, and support from Mayo Foundation. Study data included samples collected through the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona, USA. The Brain and Body Donation Program is supported by the NINDS (U24 NS072026, National Brain and Tissue Resource for Parkinson’s Disease and Related Disorders); the NIA (P30 AG19610, Arizona Alzheimer’s Disease Core Center); the Arizona Department of Health Services (contract 211002, Arizona Alzheimer’s Research Center); the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901, and 1001, to the Arizona Parkinson’s Disease Consortium); and the Michael J. Fox Foundation for Parkinson’s Research. AUTTX LLC is supported by funds from the Center for Neurologic Study (Dr. Richard Smith, Director). This work was supported by grants from the NIH/NINDS (R01NS112503 to DWC and CLT; R01NS080820 to NET) and NIH/NIA (R01AG061796, U19AG074879, U01AG046139 to NET), the Packard Center for ALS Research (DWC), the ALS association (DWC), ALS finding a Cure (to CLT), the Sean M. Healey and AMG Center for ALS and the Massachusetts Center for Alzheimer Therapeutic Science (MassCATS to CLT). CLT is the recipient of the Araminta Broch-Healey Endowed Chair in ALS. NET is the recipient of Alzheimer’s Association Zenith Award."